Kereos
Saint Louis
About Kereos
Kereos, Inc., a biotechnology company, develops targeted molecular imaging agents and therapeutics to detect and treat cancer and cardiovascular disease. The company offers KI-0001, a magnetic resonance imaging (MRI) agent for tumor detection that finds tumors and highlights growing regions in the tumor margin; and KI-100X, a targeted chemotherapeutics for solid tumors, which reduces angiogenesis in tumor and atherosclerosis models, as well as inhibits tumor growth. It also provides KI-0002, an MRI agent for cardiovascular disease detection via an undisclosed biomarker; KI-1004, an anti-restenotic that inhibits restenosis while preserving re-endotheliazation in angioplasty models; and KM-4419, a targeted chemotherapeutic for solid tumors that synergizes with several chemotherapeutics in blocking tumor growth and increasing survival. In addition, the company works with pharmaceutical and imaging companies for the development and commercialization of cardiovascular disease MRI agents, as well as development of molecular imaging systems. Kereos, Inc. was founded in 1999 and is based in St. Louis, Missouri.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $27.2M
- Last round: Debt Financing (Sep 2014)
- Website: kereos.com
- Phone: 314-633-1879
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Canonical: https://fsome.com/organization/kereos-2775062 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.